Skip to main content

Table 2 Comparison of neurological manifestation/disorder to total patients of each study

From: Neurologic manifestations of COVID-19 infection in Asia: a systematic review

Author

Study methods

Neurological manifestation/disorder

Number of patients with neurological manifestation/disorder

Total number of patients

Koh JS and colleagues [4]

Prospective multi-center cohort study

Acute disseminated encephalomyelitis (ADEM) and encephalitis

4 (4.4%)

90 patients

Cerebrovascular disorder (AIS/TIA)

19 (21.1%)

Cerebral venous thrombosis

4 (4.4%)

Intracerebral hemorrhage

2 (2.2%)

Peripheral nervous system disorder (mono/polyneuropathy)

7 (7.8%)

Dysautonomia

4 (4.4%)

Mao and colleagues [5]

Retrospective, observational study

Dizziness

36 (16.8%)

214 patients

Headache

28 (13.1%)

Impaired consciousness

16 (7.5%)

Acute cerebrovascular disease

6 (2.8%)

Ataxia

1 (0.5%)

Seizure

1 (0.5%)

Taste impairment (dysgeusia/ageusia)

12 (5.6%)

Smell impairment (hyposmia/anosmia)

11 (15.1%)

Vision impairment

3 (1.4%)

Nerve pain

5 (2.3%)

Lu and colleagues [6]

Retrospective multi-center study

Acute symptomatic seizure

304 (100%)

304 patients

Chandrasekaran and colleagues  [7]

Case report

Acute ischemic stroke

1 (100%)

1 patient

Kamal YM and colleagues [8]

Case report

Encephalitis

1 (100%)

1 patient

Khalifa and colleagues [9]

Case report

Guillain-Barré syndrome

1 (100%)

1 patient

Wang and colleagues [10]

Case report

Mental abnormalities associated COVID-19

1 (100%)

1 patient

Kwon and colleagues [11]

Case series

Acute ischemic stroke

5 (100%)

5 patients

Wada S and colleagues [12]

Case report

Guillain-Barré syndrome

1 (100%)

1 patient